PD-L1 antibody hybridized with the extracellular domain of TGFBRII promotes the anti-cancer effects of PD-L1, the inhibition of TGF-β by PD-L1 enhances the activation of immune cells to destroy tumor cells [177]. Here, TGFB1 is linked to cancer.